Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop Trial
Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop Trial
复制标题
DOI：
10.1089/dia.2021.0524
复制
发表时间：
2022-02-08
影响因子：
5.4
通讯作者：
Buckingham, Bruce A.
中科院分区：
文献类型：
--
作者：
Ekhlaspour, Laya;Town, Marissa;Buckingham, Bruce A.
使用闭环系统可显著改善1型糖尿病（T1 D）患者在70-180 mg/dL范围内的时间（TIR）。在一项为期6个月的RCT中，112例受试者在获得传感器增强胰岛素泵治疗的2周基线动态血糖监测（CGM）数据后被随机分配至闭环对照组（串联控制-IQ）。我们比较了按基线HbA 1c水平分类的亚组从基线到研究结束的血糖结果。所有HbA 1c亚组均显示TIR改善，原因是高血糖和低血糖降低。HbA 1c = 8.5%的患者主要通过降低日间和夜间高血糖来改善，这是由于日间自动基础胰岛素调整和校正推注。似乎没有任何理由根据HbA 1c将T1 D患者排除在自动胰岛素输注之外。临床试验标识符：NCT 03563313。
Using a closed-loop system significantly improves time in range (TIR) 70-180 mg/dL in patients with type 1 diabetes (T1D). In a 6-month RCT, 112 subjects were randomly assigned to closed-loop control (Tandem Control-IQ) after obtaining 2 weeks of baseline Continuous glucose monitoring (CGM) data from sensor-augmented pump therapy. We compared glycemic outcomes from baseline to end of study among subgroups classified by baseline HbA1c levels. All HbA1c subgroups showed an improvement in TIR due to reduction of both hyperglycemia and hypoglycemia. Those with HbA1c = 8.5% improved mostly by reducing daytime and nocturnal hyperglycemia due to both automated basal insulin adjustments and correction boluses during the day. There does not appear to be any reason to exclude individuals with T1D from automated insulin delivery based on their HbA1c. Clinical Trial Identifier: NCT03563313.